About Abid Ansari
Abid Ansari is a chief financial officer at General Oncology.
Abid Ansari reports to the SEC as an officer of 1 public company: Precision Biosciences (DTIL).
Abid Ansari first appears on SEC filings in 2019.
Experience
This experience comes from Abid Ansari's profile and from SEC filings. For roles taken from filings, the years are when the filings name Abid Ansari in the role, so the role may have started earlier or lasted longer.
AL
Ansari Consulting LLC Current
Strategic Financial Advisor
2020 – Present
General Oncology, Inc.
Chief Financial Officer
2024 – 2026 · Newton, MA
Develops experimental treatments for people with metastatic cancer and other proliferative diseases.
OI
OncoC4, Inc.
Chief Financial Officer
2023 – 2024
AL
Artios Pharma Ltd
Chief Financial Officer
2021 – 2023
PI
Precision Biosciences Inc.
Chief Financial Officer
2016 – 2021 · Public company (DTIL)
GS
GSK
Sr. Director Deal Finance and M&A, World Wide Business Development
2013 – 2016
GL
GlaxoSmithKline
Sr. Director, Head of Portfolio Analysis Group, R&D
2011 – 2013
ME
MedImmune
Associate Director, Capital Finance
2006 – 2011
II
Imperial Chemical Industries (ICI)
Plant Controller
2003 – 2006
EX
ExxonMobil
Process Engineer Cooperative Education Program
1998 – 2000
Key Colleagues at Startups
The people Abid Ansari works with at each company, as listed on that company's latest Form D.
General Oncology, Inc. · Form D, Apr 23, 2026
BS
Barry Seeman
Director
AG
Arnold Glazier
Chief Scientific Officer and director
MP
Michael Petit
Director
JG
Jeffrey Glazier
Chief Executive Officer and director